title: Double-blind comparison of pantoprazole and omeprazole for the treatment of acute duodenal ulcer.
abstract: OBJECTIVE
  To compare the healing rates of acute duodenal ulcer in patients receiving pantoprazole 40 mg or omeprazole 20 mg once daily and to assess drug tolerance.
  
  
  METHODS
  Randomized, double-blind study evaluating patients with healed duodenal ulcer on endoscopy after 2 weeks of treatment and patients unhealed at 2 and after 4 weeks of treatment.
  
  
  METHODS
  Hospital or private gastroenterology practice outpatients.
  
  
  METHODS
  Men or women, aged at least 18 years, with one or two duodenal ulcers. Patients with ulcer complications or with other significant acid-related disease were excluded. A total of 270 patients entered the study, of whom 255 were included in the per-protocol analysis.
  
  
  RESULTS
  The primary measure of efficacy was the healing rates of duodenal ulcers. Complete healing of ulcers was observed in 88 (71%) of the 124 patients in the pantoprazole group and in 85 (65%) of the 131 patients in the omeprazole group after 2 weeks of treatment. The cumulative healing rates after 4 weeks were 118 (95%) out of 124 and 117 (89%) out of 131 patients, respectively. There was no significant difference between treatment groups with respect to either healing rates or freedom from ulcer pain at 2 weeks. Both treatments were well tolerated: only 10 and 11 patients in the pantoprazole and omeprazole groups, respectively, reported adverse events. Diarrhoea was reported by two patients in each group.
  
  
  CONCLUSIONS
  Pantoprazole 40 mg daily and omeprazole 20 mg daily are equally effective in inducing ulcer healing.
authors.affiliation: Hospital Sint Antoniushove, Leidschendam, The Netherlands.
authors.forename: J A
authors.initials: JA
authors.lastname: Beker
authors.forename: G
authors.initials: G
authors.lastname: Bianchi Porro
authors.forename: M A
authors.initials: MA
authors.lastname: Bigard
authors.forename: G
authors.initials: G
authors.lastname: Delle Fave
authors.forename: G
authors.initials: G
authors.lastname: Devis
authors.forename: H
authors.initials: H
authors.lastname: Gouerou
authors.forename: C
authors.initials: C
authors.lastname: Maier
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000897:Anti-Ulcer Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003967:Diarrhea / Q000139:chemically induced; D004311:Double-Blind Method; D004361:Drug Tolerance; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004384:Duodenoscopy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077402:Pantoprazole; D013454:Sulfoxides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014945:Wound Healing
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D000077402:Pantoprazole; D009853:Omeprazole